Pathogenesis of Ketosis-Prone Diabetes (KPD)
Ketosis-prone diabetes results from severe, reversible β-cell dysfunction combined with transient insulin resistance, leading to profound insulinopenia that triggers ketoacidosis, but unlike type 1 diabetes, β-cell function recovers after the acute crisis. 1
Dual Metabolic Defects at Presentation
At initial presentation with diabetic ketoacidosis, individuals with KPD demonstrate:
- Significant impairment of both insulin secretion AND insulin action 1
- Severe β-cell dysfunction that is functionally similar to type 1 diabetes during the acute phase
- Marked insulin resistance, often associated with obesity
The critical distinguishing feature is that these defects are reversible rather than permanent.
Recovery and Remission Phase
After achieving near-normoglycemia, both insulin secretion and insulin action improve to levels comparable to individuals with ketosis-resistant type 2 diabetes 1. This recovery explains why approximately 70% of KPD patients can discontinue insulin after several months and maintain acceptable glycemic control on diet or non-insulin therapies 1, 2.
Absence of Autoimmunity
Unlike type 1 diabetes, KPD lacks the autoimmune destruction of β-cells:
- Negative anti-islet autoantibodies (GAD65, IA-2, ZnT8, insulin autoantibodies) 1
- No evidence of immune-mediated β-cell destruction
- However, recent research suggests that 36.4% of KPD patients show insulin peptide-specific interferon-γ immune responses, indicating some immunological involvement may exist in certain phenotypes 3
Proposed Mechanisms of β-Cell Dysfunction
Glucotoxicity Hypothesis
A fast, reversible glucotoxicity process appears central to KPD pathogenesis 4. This mechanism:
- May exist in all individuals but is more pronounced in those susceptible to KPD
- Causes temporary β-cell inactivation during severe hyperglycemia
- Reverses when glycemic control is restored
Arginine Metabolism Defect
Recent mechanistic studies reveal a specific metabolic vulnerability in KPD 5:
- During hyperglycemia, arginine flux decreases by 42.5% more in KPD compared to type 2 diabetes
- This results from reduced arginine derived from protein breakdown
- Since arginine potentiates insulin secretion during hyperglycemia, its diminished bioavailability contributes to ketoacidosis development
- Citrulline supplementation normalizes arginine availability, suggesting a therapeutic target
Potential Serotonin Pathway Involvement
Emerging evidence suggests decreased serotonin production or action may contribute to KPD pathogenesis, as serotonin receptor antagonists can precipitate diabetic ketosis in susceptible individuals 6.
Epidemiologic and Genetic Context
KPD most frequently occurs among Blacks of African ancestry and persons who identify as Afro-Caribbean or Hispanic 1. The condition accounts for 20-50% of new-onset DKA in Black and Hispanic adults 2. While initially thought to have monogenic causes, KPD is now recognized as occurring across diverse racial and ethnic groups and may be provoked by infection 7.
Clinical Implications of Pathogenesis
The reversible nature of β-cell dysfunction distinguishes KPD management from type 1 diabetes:
- Initial phase: Severe insulinopenia requires insulin therapy
- Recovery phase: β-cell function restoration allows insulin discontinuation in most patients
- Maintenance phase: Non-insulin therapies (metformin, DPP-4 inhibitors, GLP-1 receptor agonists) can prolong remission and preserve β-cell function 2
Common pitfall: Misdiagnosing KPD as type 1 diabetes leads to unnecessary lifelong insulin therapy. The key differentiating feature is the preservation of β-cell function (β+) after recovery from the acute crisis, typically demonstrated by adequate C-peptide levels and ability to maintain glycemic control without insulin 1.